Komoriya K, Tsuchimoto M, Naruchi T, Okimura T, Yamamoto I
J Immunopharmacol. 1982;4(4):285-301. doi: 10.3109/08923978209019449.
TEI-3096 [6-p-chlorobenzyl-5H-2,3,6,7-terahydro-5,7-dioxothiazolo (3,2-a) pyrimidine], a novel thiazolopyrimidine compound has been shown to suppress adjuvant arthritis in rats without any effect on conventional inflammation. We examined the immuno-pharmacological profile of TEI-3096 in murine lymphocytes. The blastformation induced by Con A or LPS was inhibited by addition of 50-500 microM concentrations of TEI-3096. This compound suppressed elevated plaque-forming cell (PFC) response against T cell-dependent antigen. However, TEI-3096 had no effect either on normal PFC response or on antibody formation against T cell independent antigen. Although orally administered TEI-3096 had no obvious effect on anti-SRBC PFC response in normal mice, it normalized the colchicine-induced enhancement of antibody formation against TNP-HGG. TEI-3096 also enhanced the delayed type hypersensitivity in mice and rats. These results suggests that TEI-3096 restores the abnormal immune response. Therefore, it may be useful for the treatment of auto-immune disease such as rheumatoid arthritis.
TEI-3096 [6-对氯苄基-5H-2,3,6,7-四氢-5,7-二氧代噻唑并(3,2-a)嘧啶]，一种新型噻唑并嘧啶化合物，已被证明可抑制大鼠佐剂性关节炎，而对传统炎症无任何影响。我们研究了TEI-3096在小鼠淋巴细胞中的免疫药理学特征。添加50 - 500微摩尔浓度的TEI-3096可抑制由刀豆蛋白A或脂多糖诱导的细胞增殖。该化合物抑制了针对T细胞依赖性抗原的斑块形成细胞（PFC）反应升高。然而，TEI-3096对正常PFC反应或针对T细胞非依赖性抗原的抗体形成均无影响。尽管口服TEI-3096对正常小鼠的抗SRBC PFC反应无明显影响，但它使秋水仙碱诱导的针对TNP-HGG的抗体形成增强恢复正常。TEI-3096还增强了小鼠和大鼠的迟发型超敏反应。这些结果表明TEI-3096可恢复异常的免疫反应。因此，它可能对治疗类风湿性关节炎等自身免疫性疾病有用。
